Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using Artificial Intelligence

Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using Artificial Intelligence




Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using Artificial Intelligence

New Klick Applied Sciences research presented at leading AI conference

NEW YORK & TORONTO–(BUSINESS WIRE)–#AI–Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.

In findings presented Friday at the NeurIPS conference in New Orleans, Klick scientists revealed how they used machine learning and just 12 hours of data from CGMs to determine whether a patient was prediabetic or diabetic.

We have demonstrated that 12 hours of monitoring can make a big difference in the lives of people at risk of developing diabetes while there’s still time to course correct,” said Jouhyun Jeon, lead scientist of the study and principal investigator at Klick Applied Sciences. “We think CGMs could be used to not just monitor diabetes–but to prevent it altogether.”

For the study, about 600 patients who identified as healthy, prediabetic, or living with Type 2 diabetes wore a CGM device for an average of 12 days. The scientists looked at their glucose measurements over time and developed machine learning models to see if those values could be used to determine whether that person was healthy, prediabetic or diabetic.

Jeon said they discovered their 12-hour model showed similar high accuracy to results from the longer intervals, correctly identifying two-thirds of patients with prediabetes, while also showing high accuracy in identifying healthy patients and those with Type 2 diabetes. Jeon said the shorter time frame is a big step forward, adding most research draws from 10 to 14 days worth of readings, and often requires analysis from expert clinicians.

According to the CDC, prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as Type 2 diabetes. Approximately 96 million American adults—more than one in three—have prediabetes. Of those with prediabetes, more than 80 per cent don’t know they have it.

An overwhelming majority of people with early-onset diabetes are not aware of their condition and don’t consult a physician until their ability to control their blood sugar levels is irreparably damaged,” said Michael Lieberman, managing director of research and development at Klick Applied Sciences. “Our research has tremendous potential to help move blood glucose digital biomarkers into a position where they can be an invaluable tool for physicians for preventing diabetes before it starts.”

These findings are the latest in Klick’s ongoing work in the diabetes space. Their “Homeostasis as a proportional–integral control system” study, based on mathematical modeling to determine some of the underlying changes in how glucose is regulated that can cause diabetes, was published in Nature in 2020. They also presented earlier findings at the 2018 International Joint Conference on Artificial Intelligence (IJCAI) in Stockholm, Sweden.

About Klick Applied Sciences

Klick Applied Sciences’ diverse team of data scientists, engineers, and biological scientists conducts scientific research and develops AI/ML and software solutions as part of the company’s work to support commercial efforts using its proven business, scientific, medical, and technological expertise. Its 2019 Voice Assistants Medical Name Comprehension study laid the scientific foundation for rigorously testing voice assistant consumer devices in a controlled manner. Additional research in peer-reviewed journals, include “The need for artificial intelligence in digital therapeutics,” “Consensus study of risk factors and symptoms of SARS-CoV-2 (COVID-19) using biomedical literature and social media data,” and “COVID-19 has inspired global healthcare innovation.”

About Klick Group

The Klick Group of companies–Klick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs–is an ecosystem of brilliant talent collectively working to maximize their people’s and clients’ full potential. Established in 1997, Klick has teams across North America, with offices in New York, Philadelphia, and Toronto, and is opening global offices in Basel, Buenos Aires, London, Munich, Paris, Singapore, São Paulo, and Tokyo. Klick has consistently been named a Best Managed Company and Great Place to Work. In 2021, the company was recognized with 15 Best Workplace awards, including Best Workplaces for Women, Best Workplaces for Inclusion, Best Workplaces for Giving Back, Fast Company’s Best Workplaces for Innovators, and FORTUNE’s Best Workplaces for Millennials.

For more information, or a copy of the abstract, please contact Amanda Ferguson at pr@klick.com or 416-214-4977.

Contacts

Amanda Ferguson

pr@klick.com or 416-214-4977